<DOC>
	<DOCNO>NCT00868907</DOCNO>
	<brief_summary>Randomized , open-label , single dose , 3-treatment , 3-period crossover study , 14- 17-day washout period dos . The study consist screen visit , study center admission ( precede Treatment Periods 1 , 2 3 ) , 3 treatment period ( 4 day ) , 1 washout period ( 14 17 day separate period 1 , 2 3 ) , exit procedure .</brief_summary>
	<brief_title>Study Assessing Dosing Time Calcium Vitamin D Relative BA 35 mg DR Risedronate Dosed With Food</brief_title>
	<detailed_description />
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>female , 40 70 year age nonlactating either surgically sterile postmenopausal body mass index less equal 32 kg/m2 screening use bisphosphonate within 1 month history GI disease use medication within 714 day prior schedule dosing day</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>